Enovis Corp (ENOV) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook

GuruFocus.com
02-27
  • Revenue: Fourth quarter sales of $561 million, up 23% year-over-year and 7% on a constant currency basis.
  • Adjusted EBITDA Margin: Expanded by 210 basis points to 20.1% in the fourth quarter.
  • Adjusted Gross Margin: Increased by 150 basis points to 60.1% year-over-year in the fourth quarter.
  • Recon Revenue Growth: 59% reported global revenue growth; 10% growth on a comparable basis.
  • US Recon Growth: 7% growth, including 10% in US Extremities and 8% in Hip Knees.
  • International Growth: 13% growth in the fourth quarter.
  • P&R Growth: 3% growth reflecting a stable market environment.
  • Adjusted Earnings Per Share: $0.98, an increase of 24% versus the prior year.
  • Interest Expense: $9 million for the quarter, up from $4 million in 2023.
  • Effective Tax Rate: 21% in the fourth quarter, compared to 22% last year.
  • Goodwill Impairment: Noncash technical impairment of $645 million due to a decrease in share price and market capitalization.
  • 2025 Revenue Guidance: Expected range of $2.19 billion to $2.22 billion.
  • 2025 Adjusted EBITDA Guidance: Expected range of $405 million to $415 million.
  • 2025 Adjusted EPS Guidance: Forecasted range of $3.10 to $3.25.
  • 2025 Q1 Revenue Guidance: Expected range of $555 million to $563 million.
  • 2025 Q1 Adjusted EBITDA Guidance: Expected range of $97 million to $100 million.
  • Warning! GuruFocus has detected 3 Warning Signs with ENOV.

Release Date: February 26, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Enovis Corp (NYSE:ENOV) reported a 23% growth in the fourth quarter of 2024, with a 7% increase on a constant currency comparable basis.
  • The company successfully integrated Lima, exceeding all year one goals and contributing to a 210 basis point expansion in adjusted EBITDA margins.
  • Recon segment delivered 59% reported global revenue growth, with double-digit growth in both Hip Knee and Extremities segments.
  • Fourth quarter adjusted gross margin improved by 150 basis points year-over-year, driven by favorable segment mix and Lima cost initiatives.
  • Enovis Corp (NYSE:ENOV) expects strong execution in 2025 with projected revenues between $2.19 billion to $2.22 billion, and adjusted EBITDA in the range of $405 million to $415 million.

Negative Points

  • Enovis Corp (NYSE:ENOV) recorded a noncash technical impairment of goodwill amounting to $645 million due to a sustained decrease in share price and market capitalization.
  • Interest expense increased to $9 million in the fourth quarter compared to $4 million in 2023.
  • The company anticipates negative currency headwinds of approximately 1% to 2% in 2025.
  • Potential tariff impacts from China and Mexico could represent a $3 million to $4 million exposure per month, which is not included in the 2025 guidance.
  • The company is still managing integration headwinds from the Lima acquisition, which affected US recon growth.

Q & A Highlights

Q: Matt, congratulations on a successful career, you'll definitely be missed. Two questions for me, please. I guess the first one is just wondering about your M&A strategy post Lima. We saw a successful integration in 2024. How should we think about M&A in 2025? A: Yes, Vik, first, thanks for the kind comments and for the support. From an M&A standpoint, we've gotten a lot done in the past handful of years, including the big Lima acquisition, which has had a dramatic impact on our portfolio and momentum. '25 is going to be more of a year of small bolt-ons. We have some attractive technology and channel bolt-ons in the funnel that will be helpful in accelerating the path forward, but we're still focused on completing the Lima acquisition successfully and starting to delever the company.

Q: You guided to high single-digit Recon growth in 2025. I know it's early in the year. But is there a pathway to get to double-digit recon growth this year? A: When we look at our positions in Recon, the technologies we've got, and the historical growth we've demonstrated, we certainly have multiple paths to drive double-digit growth. We've set a strategic goal for high single digits, but we believe there's room for positives and negatives that might come along quarter-to-quarter. We exited the year with healthy momentum, and there's an opportunity to ramp cross-selling into the business.

Q: One, maybe on this Q1 phasing I think the guide implies almost 10% organic. Why is it so strong? What is Day's contribution? A: Yes, Vijay, I'll take that one. We have extra days in the first quarter that will be offset in the fourth quarter. We expect two to three extra days in Q1, which will come back in the second part of the year. Overall, we feel like we'll get off to a strong start, partly due to Days, but also due to the momentum building in the business.

Q: And maybe my follow-up on the margin guidance. Ben, I think when my math looks like maybe we're looking at 25, 30 basis points of margin expansion for fiscal '25. Is that right? A: The margin expansion guidance we've given is 60 to 70 basis points of improvement versus 2024. That's our normal 50 basis points from core operating leverage and mix, plus 20 to 30 basis points from year two synergies on the Lima side. We expect another strong year of margin improvement for the company in 2025.

Q: You touched on this briefly in the last question, but maybe you could just take sort of US, OUS, large joint versus extremities and talk about what you're seeing in the market, how it ended '24 versus started? A: Through the front half of last year, we saw strong market growth outside the US. In Q3, there was some normalization, but Q4 finished strong. We beat Q4 on the Recon side, driven by a strong finish outside the US. In the US, the year started softer, but markets improved, and we executed more share gain versus the market in the second half. We feel good about the arc of the business as we bring new products in.

Q: Maybe just a quick follow-up on free cash flow and debt. It ended up about $65 million, $70 million negative for 2024. I see you're expecting positive free cash flow in 2025. A: We see a clear pathway to 70% to 80% free cash flow conversion over time as we get past heavy investments. We'll make a strong step in the positive direction in 2025, and in 2026, you'll see a big step down in expenses related to integration and EU MDR. We're at about 3.5 times leverage now and expect to be in the low threes by the end of the year.

Q: Just help me out, did you guys mention pricing assumptions for 2025? A: On the Recon side, we expect to get back to some amount of downward price pressure, assuming a point or two of downward price pressure. On the P&R side, we think it's more of a flat price business. We have good muscle to keep us in a flat price zone in a normal environment and work price through the system in an inflationary environment.

Q: First on Lima integration, not to nitpick wording too much here, but it sounds like the wording you guys are using, is that integration is largely complete. What are the last kind of milestones? A: The key channel integration is complete in the US and most large countries outside the US. We've combined product roadmaps, leadership teams, and sales teams. Now, we transition to project execution on back-office projects, operational transfers, and development projects. The risk profile of these is different, and we're confident in executing them.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10